Antonio Jimeno

5PUBLICATIONS
43CO-AUTHORS
Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 18, 2026
Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

|Oct 23, 2025
Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts.

J Jason Morton, Stephan A Ramos, Nathaniel Alzofon

|Jun 14, 2025
First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer.

Ryan J Sullivan, Oladapo O Yeku, Deanna Teoh

|Dec 12, 2024
Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study.

Loren Michel, Antonio Jimeno, Ammar Sukari

|Jun 30, 2023
The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.

Cera Nieto, Bettina Miller, Nathaniel Alzofon

Pageof 1

Frequent Collaborators

2 joint publications

Cera Nieto

2 joint publications

Dexiang Gao

2 joint publications

Khanh T Do

1 joint publications

Loren Michel